Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01391884
Other study ID # H-2-2009-158-UREMINC
Secondary ID
Status Completed
Phase N/A
First received July 11, 2011
Last updated September 18, 2012
Start date June 2011
Est. completion date June 2012

Study information

Verified date September 2012
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Dataprotection AgencyDenmark: Ethics Committee
Study type Observational

Clinical Trial Summary

The prevalence of type 2 diabetes (T2D) is increasing rapidly worldwide. T2D is characterized by a severely impaired incretin effect. The incretin effect refers to the insulinotropic action of the nutrient-released incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The incretin effect is defined as the difference in insulin secretory responses between oral and isoglycaemic intravenous glucose challenges (OGTT and IIGI, respectively) and in healthy individuals it accounts for as much as 70% of the insulin response following oral glucose, whereas patients with T2D exhibit an incretin effect in the range of 0 to 30%. Patients with T2D and non-diabetic patients with severe kidney failure share several pathophysiological characteristics, including decreased insulin sensitivity, fasting hyperinsulinaemia and impaired beta-cell function. The reason for these findings remains to be fully elucidated. An ongoing study in our research group is investigating the incretin effect and the incretin hormone secretory responses following OGTT, IIGI and meal ingestion, respectively. In continuation of this study, essential knowledge of metabolism of incretin hormones in an uremic milieu will be obtained in the present study prior to evaluation of the use of incretin-based agents in patients with impaired kidney function. In this second study we evaluate the elimination and biodegradation of GLP-1 and GIP. The biological active incretin hormones are rapidly degraded by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4), generating inactive metabolites. The active hormones are however also eliminated by renal clearance, although the importance of this remains questionable. It is likely that the degradation and elimination of the active hormones will be significantly affected in patients with severe kidney impairment.

We hypothesize that elimination and biodegradation of the two incretin hormones, both in it´s active and inactive forms, will be affected in non-diabetic patients with severe kidney failure.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 90 Years
Eligibility 1)

Inclusion Criteria:

- Male or female; aged 18-90 years

- CKD stage 5 in chronic maintenance dialysis treatment

- BMI: 18,5-28 kg/m2

- Normal fasting plasma glucose (<6,1 mM)

- Normal or impaired glucose tolerance (PG120 min <11,1 mM following OGTT)

Inclusion Criteria:

- Male or female; aged 18-90 years

- Healthy including normal kidney function

- BMI: 18,5-28 kg/m2

- Normal fasting plasma glucose (<6,1 mM)

- Normal or impaired glucose tolerance (PG120 min <11,1 mM following OGTT)

1+2)

Exclusion Criteria:

- Diabetes mellitus

- Chronic pancreatitis / previous acute pancreatitis

- Treatment with oral glucocorticoids, calcineurin inhibitors, thiazides, dipeptidyl peptidase 4 (DPP4) inhibitors or other drugs, which could interfere with glucose or lipid metabolism

- Inflammatory bowel disease

- Malignant disease

- Bowel resection

- Severe anemia (hemoglobin <6.5 mmol/L)

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Bo Feldt-Rasmussen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intact GLP-1 concentration During GLP-1 infusion 0-60 min -60 min - 180 min No
Primary Total GLP-1 concentration GLP-1 infusion 0-60 min -60 min - 180 min No
Primary Intact GIP concentration GIP infusion 0-60 min - 60 min - 180 min No
Primary Total GIP infusion GIP infusion 0-60 min -60 min - 180 min No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT00577967 - Gabapentin - A Solution to Uremic Pruritus? N/A
Completed NCT01583309 - Effects of Convective Therapies in Dialysis Patients Phase 3
Completed NCT03437538 - Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter N/A
Completed NCT00649298 - A Clinical Trial of IntensiVE Dialysis Phase 4
Completed NCT05750875 - Gabapentin Versus Loratadine in Uremic Pruritus Phase 4
Recruiting NCT01408797 - Clonal Deletion on Living-Relative Donor Kidney Transplantation Phase 1/Phase 2
Completed NCT01267760 - Clinical and Biochemical Effects of Multipass Hemodialysis Phase 2
Recruiting NCT00375635 - Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis N/A
Recruiting NCT05076318 - Dysregulated Urea-synthesis at Terminal Uremia N/A
Completed NCT05899283 - A Comparative Study of Two Kinds of Hemodialysis Filters N/A
Completed NCT04768309 - Impact of Intestinal Microbiota on Uremic Toxins Productions N/A
Not yet recruiting NCT05386433 - Paxlovid in the Treatment of COVID-19 Patients With Uremia Early Phase 1
Completed NCT00442819 - Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Phase 4
Not yet recruiting NCT02266238 - Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial N/A
Recruiting NCT01766895 - Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
Completed NCT00388648 - Very Low Protein Diet or Dialysis in Uremic Elderly? Phase 4
Withdrawn NCT03416192 - 12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter. N/A
Recruiting NCT02446535 - Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW? N/A
Recruiting NCT02606955 - Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test N/A
Completed NCT02050139 - L-Cysteine in Peritoneal Dialysis Phase 2